Product Code: GMDHC11408IDB
Summary:
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 3, 3, 7, 14, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Erectile Dysfunction - Overview
- Erectile Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Erectile Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Erectile Dysfunction - Companies Involved in Therapeutics Development
- Aquestive Therapeutics Inc
- Astellas Pharma Inc
- Biozeus Pharmaceutical SA
- Can-Fite BioPharma Ltd
- CardioVascular BioTherapeutics Inc
- Cure Pharmaceutical Inc
- Fabre-Kramer Pharmaceuticals Inc
- Futura Medical Plc
- Hemostemix Inc
- Humanetics Corp
- Karessa Pharma Holding AB
- Mezzion Pharma Co Ltd
- Mitsubishi Tanabe Pharma Corp
- NAL Pharmaceuticals Ltd
- Pharmicell Co Ltd
- Saniona AB
- SK Chemicals Co Ltd
- Suda Pharmaceuticals Ltd
- Targazyme Inc
- XuanZhu Pharma Co Ltd
- Yangtze River Pharmaceutical Group
- Erectile Dysfunction - Drug Profiles
- (finasteride + tadalafil) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ACP-01 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AGM-175 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- alprostadil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AN-788 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AP-185 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- avanafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BZ-371 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Cellgram-ED - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CF-602 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CVBT-141 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Drug for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- FKK-01PD - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- genistein - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ILG-F - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IPED-2015 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- libiguins - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MED-2002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- mirabegron ER - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RNAi Gene therapy to Inhibit FL2 for Erectile Dysfunction, Burns and Ophthalmology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SID-123 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sildenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sildenafil citrate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Stem Cell Therapy for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SUD-003 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil IR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TF-0092 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TPN-729 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- udenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vardenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vardenafil hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- XZP-5849 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Yonkenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Erectile Dysfunction - Dormant Projects
- Erectile Dysfunction - Discontinued Products
- Erectile Dysfunction - Product Development Milestones
- Featured News & Press Releases
- Oct 28, 2019: New clinical data provide additional validation for the safety and efficacy of Futura Medical's topical MED2005 in the treatment of erectile dysfunction
- Oct 21, 2019: Final dosing of last patient in MED2005 phase 3 study
- Oct 15, 2019: Futura Medical to present data on MED2005 for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of SMSNA and Host Advisory Meeting
- Sep 27, 2019: Initiator Pharma starts dosing of last the patients in the IPED2015 clinical trial
- Sep 03, 2019: Initiator Pharma receives commitment of support for IPED2015 from Innovation Fund Denmark
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
